BRITISH COLUMBIA, Canada, July 31 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (TSX VENTURE: IXS; OTC Bulletin Board: IXSBF) (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, will present at IBC's 13th Annual World Congress Drug Discovery & Development of Innovative Therapeutics (DDT) Conference being held in Boston at the World Trade Center Boston & Seaport Hotel. The InNexus presentation will be within the Main Conference beginning at 9:40 AM (ET) on Wednesday, August 6th, held in the amphitheater at the World Trade Center Boston.
Dr. Thomas Kindt, Chief Scientific Officer will present an in-depth presentation on a Case Study of InNexus' preclinical candidate DXL625 (CD20): A New Platform for Augmenting Antibody Therapeutics for Cancer. Chairman and CEO, Jeff Morhet will also provide a company overview, including information about InNexus' unique business strategy, its DXL(TM) technology platform and upcoming company milestones. Investors, venture capitalists, company executives, scientists and other industry leaders will attend the conferences.
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management
based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own
in-house developmental facilities. These development resources provide
validation of protein and peptide discoveries, enabling InNexus (and its
strategic partners) to advance novel drug therapeutics and diagnostics. To
learn more a
|SOURCE InNexus Biotechnology Inc.|
Copyright©2008 PR Newswire.
All rights reserved